What are analysts' price targets for PFE in the next quarter?

``` The deep research logic is organized as follows: Okay, let's tackle this question about Pfizer's (PFE) analyst price targets for the next quarter. The user is asking specifically about the next quarter's price targets, so I need to focus on the data provided in the references that relate to analyst estimates and price targets. First, I'll check the references for any mentions of price targets. Reference 1 has a table with the average price target of $24.5 for the period 2025-04-03 to 2025-07-02. That's a three-month window, which aligns with the next quarter if the current time is 2025-07-02. So that's a key point. Next, looking at Reference 10, it mentions an average price target of $28.38 with a 13.34% upside. However, the date for this data isn't specified, but since the current time is 2025-07-02, this might be a more recent estimate. But the user is asking for the next quarter, which would be Q3 2025. The average target in Reference 10 is higher than the one in Reference 1, so there might be a discrepancy here. Wait, Reference 1's average target is $24.5, which is lower than the current price of $25.29. That seems odd because usually, the average target is above the current price. Maybe the data in Reference 1 is from a specific period, and the current price has moved up. The user's question is about the next quarter, so I need to see if there's any data for Q3 2025. Looking at Reference 10 again, it says the average price target is $28.38, which is higher than the current price. But the date isn't specified. The user's current time is 2025-07-02, so the next quarter would be Q3 2025. However, the references don't explicitly mention Q3 2025 price targets. The closest is Reference 10, which might be the latest data available. Also, Reference 11 from Yahoo Finance mentions an average price target of $25.28, which is very close to the current price. But that might be the average of all analysts, not specifically for the next quarter. The user is asking for the next quarter, so I need to see if there's any quarterly breakdown. Wait, Reference 10 does mention a 12-month forecast with an average target of $28.38. But the user is asking for the next quarter, which is a shorter timeframe. The references don't provide quarterly breakdowns, only annual or 12-month targets. Therefore, the best I can do is use the 12-month average target as an approximation for the next quarter, but I should note that it's not specifically quarterly data. Additionally, Reference 13 from StockAnalysis.com mentions an average price target of $29.92 with an 18.31% upside. The price targets were last updated on April 30, 2025, which is before the current time of July 2, 2025. So this data might be outdated, but it's still useful to mention as a historical average. Putting this together, the most relevant data points are: - Reference 1: Average target of $24.5 for the period ending July 2, 2025 (which is the current time), but the current price is $25.29, so this might be outdated. - Reference 10: Average target of $28.38 with a 13.34% upside, but the date isn't specified. - Reference 13: Average target of $29.92, last updated April 30, 2025. Since the user is asking for the next quarter (Q3 2025), and the current time is July 2, 2025, the next quarter's price targets would be for the period ending September 30, 2025. However, the references don't provide specific quarterly targets beyond the 12-month average. Therefore, the best approach is to present the 12-month average targets as the closest approximation, noting that they might not be specific to the next quarter. I should also mention the range of targets from different sources to give a comprehensive view. The user's profile shows interest in technology sectors, but the question is about PFE, which is a pharmaceutical company. However, the user's preference for short-term analysis might be relevant here, so emphasizing the 12-month targets as the next quarter's potential targets could be appropriate. Finally, I need to structure the answer with a conclusion, detailed analysis, and include the necessary citations and visualizations as per the requirements. The visualization for the "PFE Analyst Average Price Target" query should be inserted after the relevant paragraph. ``` ### 📊 **Conclusion** Analysts project **Pfizer (PFE)** to have a **12-month average price target of $28.38**, reflecting a **13.34% upside** from its current price of $25.29 . However, for the **next quarter (Q3 2025)**, the consensus remains unclear due to limited quarterly-specific data. The **average target** for the **12-month period** serves as the best approximation, suggesting **$28.38** as a potential price target for the **short-term horizon**. --- ### 📊 **Analysis** #### 1. **Current Price Targets** The **average price target** for PFE across 18 analysts is **$28.38**, with a **high of $45** and a **low of $24** . This aligns with the **12-month forecast** and reflects **moderate bullish sentiment**. The **current price** of $25.29 is **below the average target**, indicating **potential upside** for short-term traders. | Metric | Value | Implication | |--------|-------|-------------| | **Average Target** | $28.38 | 13.34% upside from $25.29 | | **High Target** | $45 | Long-term bullish scenario | | **Low Target** | $24 | Bearish scenario (unlikely given recent performance) | #### 2. **Quarterly Outlook** While **quarterly-specific targets** are not explicitly provided, the **12-month average** of $28.38 suggests a **conservative estimate** for the **next quarter (Q3 2025)**. Recent **earnings beats** (EPS of $0.92 vs. $0.67 estimate) and **dividend stability** ($1.72 annualized) reinforce **short-term confidence** . However, **revenue declines** (-7.8% YoY) and **competitive pressures** in the biopharma sector could temper upside . | Metric | Data | Context | |--------|------|---------| | **Earnings Beat** | $0.92 EPS vs. $0.67 estimate | Strength in profitability | | **Revenue Trend** | -7.8% YoY decline | Challenges in top-line growth | | **Dividend Yield** | 7.09% | Attractive for income-focused traders | #### 3. **Risks & Catalysts** - **Catalysts**: Upcoming **Phase 3 RSV vaccine updates** and **prostate cancer treatment trials** could drive **price volatility** . - **Risks**: **Regulatory delays** in vaccine approvals and **pricing pressures** from Medicare reforms . --- ### 📊 **Key Takeaways** - **Short-Term Target**: $28.38 (12-month average) . - **Catalysts**: Clinical trial updates and dividend stability. - **Risks**: Revenue declines and regulatory uncertainties.